SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 210.49 |
| Enterprise Value ($M) | 280.89 |
| Book Value ($M) | -28.64 |
| Book Value / Share | -0.16 |
| Price / Book | -7.35 |
| NCAV ($M) | -46.60 |
| NCAV / Share | -0.27 |
| Price / NCAV | -4.52 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.33 |
| Return on Assets (ROA) | -0.20 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.64 |
| Current Ratio | 1.86 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 99.27 |
| Assets | 117.22 |
| Liabilities | 145.87 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 115.78 |
| Operating Income | -21.59 |
| Net Income | -25.09 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -5.74 |
| Cash from Investing | -4.30 |
| Cash from Financing | 18.37 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Armistice Capital, Llc | 9.81 | 0.85 | |
| 13G/A | Vanguard Group Inc | 5.13 | -25.91 | |
| 13G | Morgan Stanley | 8.30 | ||
| 13G/A | Goldman Sachs Group Inc | 0.10 | -97.27 | |
| 13G/A | Soleus Capital Master Fund, L.P. | 5.40 | 2.38 | |
| 13G/A | BlackRock Inc. | 8.70 | 3.52 | |
| 13G/A | Fmr Llc | 0.12 | -97.74 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 177,881 | 630,967 | 28.19 | |
| 241,292 | 791,587 | 30.48 | |
| 185,493 | 270,756 | 68.51 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| REPL – Replimune Group, Inc. | RGEN – Repligen Corporation |
| RGNX – REGENXBIO Inc. | RLMD – Relmada Therapeutics, Inc. |
| RLYB – Rallybio Corporation |